Mental health provider Braxia Scientific to acquire KetaMD for $6 million

KetaMD is a telehealth platform that provides affordable, home-based ketamine treatment for people with anxiety, depression, and related mental illnesses. Treatment provided by KetaMD is medically supervised, directed by registered nurses with expertise in mental health, and supported by psychiatrists and depression researchers. The company applies ketamine to telemedicine, following best practices and professional treatment guidelines. Recently, Toronto, Canada-based mental health company Braxia Scientific recently announced that it will acquire KetaMD in a transaction valued at approximately $6 million.

This article is reprinted from:
This site is for inclusion only, and the copyright belongs to the original author.

Leave a Comment

Your email address will not be published.